Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment

One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-01, Vol.36 (1), p.97-100
Main Authors: Fleming, Catherine A., Craven, Donald E., Thornton, David, Tumilty, Sheila, Nunes, David
Format: Article
Language:English
Subjects:
Adult
AIDS
Antiviral Agents - therapeutic use
Biological and medical sciences
Biopsies
Drug Therapy, Combination
Eligibility Determination
Female
Genotypes
Hepacivirus
Hepatitis C - complications
Hepatitis C - drug therapy
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV/AIDS
Human viral diseases
Humans
Infections
Infectious diseases
Interferons - therapeutic use
Liver
Liver diseases
Male
Medical sciences
Mental illness
Middle Aged
Prospective Studies
Ribavirin - therapeutic use
Urban Health
Urban Population
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323
cites cdi_FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323
container_end_page 100
container_issue 1
container_start_page 97
container_title Clinical infectious diseases
container_volume 36
creator Fleming, Catherine A.
Craven, Donald E.
Thornton, David
Tumilty, Sheila
Nunes, David
description One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.
doi_str_mv 10.1086/344907
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_72895968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4462226</jstor_id><oup_id>10.1086/344907</oup_id><sourcerecordid>4462226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323</originalsourceid><addsrcrecordid>eNqF0U2P1CAYB_DGaNx11U9gDB70VuUd6s1MVmeSSfSw6xovDaVPDWsLXaDROfnV7aTNzsl4AcL_xwPkKYrnBL8lWMt3jPMKqwfFORFMlVJU5OG8xkKXXDN9VjxJ6RZjQjQWj4szQnlFKNbnxZ8tjCa77BLaoK8uTgkZ36LtNBiPdsMw-dBC56wDbw8r2ATnO7DZBY-cnz26js08fgnj1Jvj9nu0D7_QZe9-uMb1Lh9QFyLa-Qyxgzgfu4pg8gA-Py0edaZP8GydL4rrj5dXm225__xpt_mwLy0XLJeWUmCdUS2d3902RkhjMW9AaCmMlp1slLSgKmuIZC1tqdCqo0AogDYto-yieLPUHWO4myDlenDJQt8bD2FKtaK6EpXU_4VEa8Irpk7QxpBShK4eoxtMPNQE18ee1EtPZvhyrTg1A7QntjZhBq9XYJI1fReNty6dHOdScXX8w6vFhWn892UvFnObcoj3ai5BKZVzXC6xSxl-38cm_qylYkrU22_fa8z2NzeY7GvJ_gIKpbbU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18814937</pqid></control><display><type>article</type><title>Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment</title><source>JSTOR Archival Journals and Primary Sources Collection【Remote access available】</source><source>Oxford Journals Online</source><creator>Fleming, Catherine A. ; Craven, Donald E. ; Thornton, David ; Tumilty, Sheila ; Nunes, David</creator><creatorcontrib>Fleming, Catherine A. ; Craven, Donald E. ; Thornton, David ; Tumilty, Sheila ; Nunes, David</creatorcontrib><description>One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/344907</identifier><identifier>PMID: 12491208</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; AIDS ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Biopsies ; Drug Therapy, Combination ; Eligibility Determination ; Female ; Genotypes ; Hepacivirus ; Hepatitis C - complications ; Hepatitis C - drug therapy ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV/AIDS ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Interferons - therapeutic use ; Liver ; Liver diseases ; Male ; Medical sciences ; Mental illness ; Middle Aged ; Prospective Studies ; Ribavirin - therapeutic use ; Urban Health ; Urban Population ; Viral diseases ; Viral hepatitis</subject><ispartof>Clinical infectious diseases, 2003-01, Vol.36 (1), p.97-100</ispartof><rights>Copyright 2003 The Infectious Diseases Society of America</rights><rights>2003 by the Infectious Diseases Society of America 2003</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323</citedby><cites>FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4462226$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4462226$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14467472$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12491208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleming, Catherine A.</creatorcontrib><creatorcontrib>Craven, Donald E.</creatorcontrib><creatorcontrib>Thornton, David</creatorcontrib><creatorcontrib>Tumilty, Sheila</creatorcontrib><creatorcontrib>Nunes, David</creatorcontrib><title>Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.</description><subject>Adult</subject><subject>AIDS</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biopsies</subject><subject>Drug Therapy, Combination</subject><subject>Eligibility Determination</subject><subject>Female</subject><subject>Genotypes</subject><subject>Hepacivirus</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV/AIDS</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferons - therapeutic use</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental illness</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Ribavirin - therapeutic use</subject><subject>Urban Health</subject><subject>Urban Population</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqF0U2P1CAYB_DGaNx11U9gDB70VuUd6s1MVmeSSfSw6xovDaVPDWsLXaDROfnV7aTNzsl4AcL_xwPkKYrnBL8lWMt3jPMKqwfFORFMlVJU5OG8xkKXXDN9VjxJ6RZjQjQWj4szQnlFKNbnxZ8tjCa77BLaoK8uTgkZ36LtNBiPdsMw-dBC56wDbw8r2ATnO7DZBY-cnz26js08fgnj1Jvj9nu0D7_QZe9-uMb1Lh9QFyLa-Qyxgzgfu4pg8gA-Py0edaZP8GydL4rrj5dXm225__xpt_mwLy0XLJeWUmCdUS2d3902RkhjMW9AaCmMlp1slLSgKmuIZC1tqdCqo0AogDYto-yieLPUHWO4myDlenDJQt8bD2FKtaK6EpXU_4VEa8Irpk7QxpBShK4eoxtMPNQE18ee1EtPZvhyrTg1A7QntjZhBq9XYJI1fReNty6dHOdScXX8w6vFhWn892UvFnObcoj3ai5BKZVzXC6xSxl-38cm_qylYkrU22_fa8z2NzeY7GvJ_gIKpbbU</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Fleming, Catherine A.</creator><creator>Craven, Donald E.</creator><creator>Thornton, David</creator><creator>Tumilty, Sheila</creator><creator>Nunes, David</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20030101</creationdate><title>Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment</title><author>Fleming, Catherine A. ; Craven, Donald E. ; Thornton, David ; Tumilty, Sheila ; Nunes, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biopsies</topic><topic>Drug Therapy, Combination</topic><topic>Eligibility Determination</topic><topic>Female</topic><topic>Genotypes</topic><topic>Hepacivirus</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV/AIDS</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferons - therapeutic use</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental illness</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Ribavirin - therapeutic use</topic><topic>Urban Health</topic><topic>Urban Population</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fleming, Catherine A.</creatorcontrib><creatorcontrib>Craven, Donald E.</creatorcontrib><creatorcontrib>Thornton, David</creatorcontrib><creatorcontrib>Tumilty, Sheila</creatorcontrib><creatorcontrib>Nunes, David</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleming, Catherine A.</au><au>Craven, Donald E.</au><au>Thornton, David</au><au>Tumilty, Sheila</au><au>Nunes, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>36</volume><issue>1</issue><spage>97</spage><epage>100</epage><pages>97-100</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>12491208</pmid><doi>10.1086/344907</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2003-01, Vol.36 (1), p.97-100
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_72895968
source JSTOR Archival Journals and Primary Sources Collection【Remote access available】; Oxford Journals Online
subjects Adult
AIDS
Antiviral Agents - therapeutic use
Biological and medical sciences
Biopsies
Drug Therapy, Combination
Eligibility Determination
Female
Genotypes
Hepacivirus
Hepatitis C - complications
Hepatitis C - drug therapy
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV/AIDS
Human viral diseases
Humans
Infections
Infectious diseases
Interferons - therapeutic use
Liver
Liver diseases
Male
Medical sciences
Mental illness
Middle Aged
Prospective Studies
Ribavirin - therapeutic use
Urban Health
Urban Population
Viral diseases
Viral hepatitis
title Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A11%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20C%20Virus%20and%20Human%20Immunodeficiency%20Virus%20Coinfection%20in%20an%20Urban%20Population:%20Low%20Eligibility%20for%20Interferon%20Treatment&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Fleming,%20Catherine%20A.&rft.date=2003-01-01&rft.volume=36&rft.issue=1&rft.spage=97&rft.epage=100&rft.pages=97-100&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/344907&rft_dat=%3Cjstor_proqu%3E4462226%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-c22e3fa7d2912dba56ac04be5865a86f6b76ce79ca163d2d2587f2e12ee8ad323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18814937&rft_id=info:pmid/12491208&rft_jstor_id=4462226&rft_oup_id=10.1086/344907&rfr_iscdi=true